Arax Advisory Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Arax Advisory Partners’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$456	Buy	+42	New	+$479	﹤0.01%	5025
2026 Q1	–	Sell	-6	Closed	-$100	–	4199
2025 Q4	$100	Sell	6 -53	-90%	-$757	﹤0.01%	3825
2025 Q3	$695	Buy	+59	New	+$609	﹤0.01%	3326
2024 Q4	–	Sell	-17	Closed	-$308	–	2668
2024 Q3	$308	Hold	17	–	–	﹤0.01%	2470
2024 Q2	$176	Buy	+17	New	+$175	﹤0.01%	2452

Other funds holding PHAT

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Arax Advisory Partners's PHAT Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Phathom Pharmaceuticals (PHAT) in Q2 2026: 42 shares worth $456. The stake represents ﹤0.01% of the portfolio and ranks #5025 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in PHAT as recently as Q4 2025.

Arax Advisory Partners first reported a position in PHAT in Q2 2024 and has held it in 5 quarters since. The position peaked at $695 in Q3 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Arax Advisory Partners held 42 shares of Phathom Pharmaceuticals worth $456 as of Q2 2026.
Phathom Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
Phathom Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5025 holding.
Arax Advisory Partners first reported a position in Phathom Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
Arax Advisory Partners's Phathom Pharmaceuticals position peaked at $695 in Q3 2025.
161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.